Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Active not recruiting 5Recruiting 4Completed 4Terminated 2Not yet recruiting 2Withdrawn 1Unknown 1Approved for marketing 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Prolymphocytic 1

Interventions

Rituximab 187Cyclophosphamide 174Etoposide 94Peripheral Blood Stem Cell Transplantation 90Vincristine 89Prednisone 80Doxorubicin 79Filgrastim 75fludarabine phosphate 60Radiotherapy 56Mycophenolic Acid 41Melphalan 41Cytarabine 41Busulfan 40Cyclosporine 39Methotrexate 37Whole-Body Irradiation 36Tacrolimus 35Carmustine 34Ifosfamide 28Lenalidomide 27Granulocyte Colony-Stimulating Factor 27Antilymphocyte Serum 27Gemcitabine 25Carboplatin 25Methylprednisolone 24ibritumomab tiuxetan 23Bortezomib 22Dexamethasone 21ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large B-Cell, Diffuse × tafasitamab × Clear all
NCT04981795 2026-04-27

realMIND

Incyte Corporation

Completed
102 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT02763319 2025-07-17

B-MIND

Incyte Corporation

Phase 2/3 Completed
453 enrolled 29 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04134936 2024-10-16

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

MorphoSys AG

Phase 1 Completed
66 enrolled 21 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02399085 2023-10-23

L-MIND

MorphoSys AG

Phase 2 Completed
81 enrolled 23 charts 1 FDA
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡